1. National Leader, Taiwan Clinical Trial Consortium for Liver Diseases
-Successful conduction of several investigator-initiated trials
-Efficient facilitation of many international and domestic multi-center clinical trials sponsored by pharmaceutical companies
2. Principal investigator, A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects with Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection
Achievements:
-Confirm that HBV co-infection does not impact HCV SVR after DAA therapy
-Prove that ledipasvir/sofosbuvir is effective for the treatment of HCV genotype 2
-Clarify risk and profile of HBV reactivation during and after DAA therapy
Clinical impacts:
-Lead to approval of ledipasvir/sofosbuvir for the treatment of HCV genotype 2 in many countries including Taiwan. The speed toward eradication of HCV infection in Taiwan national project before 2025 is facilitated.
-The sponsor had very good profit after this new indication for HCV genotype 2, which is prevalent in Asia-Pacific region.
-The safety of patients with HBV/HCV coinfection is improved due to the clarification of the risk of HBV reactivation.
3. National leader: The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis
Achievements: Integrate Taiwan sites and facilitate recruitment of suitable subjects
4. President, 2022 APASL Single Topic Conference on HCC (Asia-Pacific international conference)
5. Associate editor, Liver International, Journal of the Formosan Medical Association, Journal of Microbiology, Immunolo and Infection
6 World's Top 2% Scientists, Stanford University statistics 2020